KalVista Pharmaceuticals, Inc. Common Stock
KALV Real Time Price USDRecent trades of KALV by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Chris Jacobs House / R | Purchase $1,001 - $15,000 | Dec. 12, 2022 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by KALV's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof Aug. 29, 2023
-
Patent Title: Enzyme inhibitors Mar. 28, 2023
-
Patent Title: Solid forms of a plasma kallikrein inhibitor and salts thereof Feb. 21, 2023
-
Patent Title: Inhibitors of plasma kallikrein Feb. 08, 2022
-
Patent Title: Dosage forms comprising a plasma kallikrein inhibitor Feb. 01, 2022
-
Patent Title: Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors Jan. 25, 2022
-
Patent Title: N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors Dec. 14, 2021
-
Patent Title: Pyrazole derivatives as plasma kallikrein inhibitors Nov. 23, 2021
-
Patent Title: N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors Aug. 10, 2021
-
Patent Title: N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors May. 11, 2021
-
Patent Title: N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors Sep. 22, 2020
-
Patent Title: Polymorphs of n-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors Aug. 25, 2020
-
Patent Title: Pharmaceutical compositions Nov. 19, 2019
-
Patent Title: N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors Jul. 30, 2019
-
Patent Title: Inhibitors of plasma kallikrein Mar. 05, 2019
-
Patent Title: Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities Dec. 26, 2017
-
Patent Title: Benzylamine derivatives Dec. 05, 2017
-
Patent Title: Bicyclic inhibitors Aug. 22, 2017
-
Patent Title: Benzylamine derivatives Jun. 06, 2017
-
Patent Title: Heterocyclic derivates Jan. 03, 2017
-
Patent Title: Polymorphs of n-[(r)-1-[(s)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride Dec. 06, 2016
-
Patent Title: Benzylamine derivatives as inhibitors of plasma kallikrein Jan. 12, 2016
-
Patent Title: Benzylamine derivatives as inhibitors of plasma kallikrein Jun. 09, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of KALV in WallStreetBets Daily Discussion
Recent insights relating to KALV
Recent picks made for KALV stock on CNBC
ETFs with the largest estimated holdings in KALV
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view KALV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.